176 related articles for article (PubMed ID: 32523801)
1. Interleukin-6-knockdown of chimeric antigen receptor-modified T cells significantly reduces IL-6 release from monocytes.
Kang L; Tang X; Zhang J; Li M; Xu N; Qi W; Tan J; Lou X; Yu Z; Sun J; Wang Z; Dai H; Chen J; Lin G; Wu D; Yu L
Exp Hematol Oncol; 2020; 9():11. PubMed ID: 32523801
[TBL] [Abstract][Full Text] [Related]
2. Preclinical efficacy and safety evaluation of interleukin-6-knockdown CAR-T cells targeting at CD19.
Wen H; Huo G; Hou T; Qu Z; Sun J; Yu Z; Kang L; Wang M; Lou X; Yu L; Huo Y
Ann Transl Med; 2021 Dec; 9(23):1713. PubMed ID: 35071407
[TBL] [Abstract][Full Text] [Related]
3. [Establishment of a cytokine release syndrome associated with chimeric antigen receptor T cell treatment in SCID/Beige mice model].
Shan JQ; Nan SF; Li F; Shen CY; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1248-1254. PubMed ID: 34915632
[No Abstract] [Full Text] [Related]
4. Cytokine Release Syndrome after Treatment of Anti-CD19 CAR-T Therapy with IL-6 Knocking Down in Patients with Central Nervous System B-cell Acute Lymphocytic Leukemia.
Mao Y; Xu X
Ann Clin Lab Sci; 2021 Nov; 51(6):790-794. PubMed ID: 34921032
[TBL] [Abstract][Full Text] [Related]
5. Successful application of anti-CD19 CAR-T therapy with IL-6 knocking down to patients with central nervous system B-cell acute lymphocytic leukemia.
Chen LY; Kang LQ; Zhou HX; Gao HQ; Zhu XF; Xu N; Yu L; Wu DP; Xue SL; Sun AN
Transl Oncol; 2020 Nov; 13(11):100838. PubMed ID: 32745961
[TBL] [Abstract][Full Text] [Related]
6. Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo.
Zhou JE; Sun L; Jia Y; Wang Z; Luo T; Tan J; Fang X; Zhu H; Wang J; Yu L; Yan Z
J Control Release; 2022 Oct; 350():298-307. PubMed ID: 36002054
[TBL] [Abstract][Full Text] [Related]
7. TGF-β/IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell Lymphoma.
Noh KE; Lee JH; Choi SY; Jung NC; Nam JH; Oh JS; Song JY; Seo HG; Wang Y; Lee HS; Lim DS
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445415
[TBL] [Abstract][Full Text] [Related]
8. An In Vitro Model to Assess CRS Potential of CAR T Cells Using a Tumor Cell Line and Autologous Monocytes.
Nouri Y; Weinkove R; Perret R
Curr Protoc; 2023 Aug; 3(8):e864. PubMed ID: 37606421
[TBL] [Abstract][Full Text] [Related]
9. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
[TBL] [Abstract][Full Text] [Related]
10. Analysis of IL-6 serum levels and CAR T cell-specific digital PCR in the context of cytokine release syndrome.
Pabst T; Joncourt R; Shumilov E; Heini A; Wiedemann G; Legros M; Seipel K; Schild C; Jalowiec K; Mansouri Taleghani B; Fux M; Novak U; Porret N; Zeerleder S; Bacher U
Exp Hematol; 2020 Aug; 88():7-14.e3. PubMed ID: 32673688
[TBL] [Abstract][Full Text] [Related]
11. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs.
Ninomiya S; Narala N; Huye L; Yagyu S; Savoldo B; Dotti G; Heslop HE; Brenner MK; Rooney CM; Ramos CA
Blood; 2015 Jun; 125(25):3905-16. PubMed ID: 25940712
[TBL] [Abstract][Full Text] [Related]
12. The differential effects of tumor burdens on predicting the net benefits of ssCART-19 cell treatment on r/r B-ALL patients.
Li M; Xue SL; Tang X; Xu J; Chen S; Han Y; Qiu H; Miao M; Xu N; Tan J; Kang L; Yu Z; Lou X; Xu Y; Chen J; Yan Z; Feng W; Wu D; Yu L
Sci Rep; 2022 Jan; 12(1):378. PubMed ID: 35013456
[TBL] [Abstract][Full Text] [Related]
13. Cytokine release syndrome: grading, modeling, and new therapy.
Liu D; Zhao J
J Hematol Oncol; 2018 Sep; 11(1):121. PubMed ID: 30249264
[TBL] [Abstract][Full Text] [Related]
14. Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19
Liu Q; Xu Y; Mou J; Tang K; Fu X; Li Y; Xing Y; Rao Q; Xing H; Tian Z; Wang M; Wang J
Cytotherapy; 2020 Oct; 22(10):552-562. PubMed ID: 32747298
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients.
Taştan C; Kançağı DD; Turan RD; Yurtsever B; Çakırsoy D; Abanuz S; Yılancı M; Seyis U; Özer S; Mert S; Kayhan CK; Tokat F; Açıkel Elmas M; Birdoğan S; Arbak S; Yalçın K; Sezgin A; Kızılkılıç E; Hemşinlioğlu C; İnce Ü; Ratip S; Ovalı E
Turk J Haematol; 2020 Nov; 37(4):234-247. PubMed ID: 32755128
[TBL] [Abstract][Full Text] [Related]
16. Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy.
Huarte E; O'Connor RS; Peel MT; Nunez-Cruz S; Leferovich J; Juvekar A; Yang YO; Truong L; Huang T; Naim A; Milone MC; Smith PA
Clin Cancer Res; 2020 Dec; 26(23):6299-6309. PubMed ID: 32998963
[TBL] [Abstract][Full Text] [Related]
17. Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators.
Sachdeva M; Duchateau P; Depil S; Poirot L; Valton J
J Biol Chem; 2019 Apr; 294(14):5430-5437. PubMed ID: 30804212
[TBL] [Abstract][Full Text] [Related]
18. Influence of Retronectin-Mediated T-Cell Activation on Expansion and Phenotype of CD19-Specific Chimeric Antigen Receptor T Cells.
Stock S; Hoffmann JM; Schubert ML; Wang L; Wang S; Gong W; Neuber B; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
Hum Gene Ther; 2018 Oct; 29(10):1167-1182. PubMed ID: 30024314
[TBL] [Abstract][Full Text] [Related]
19. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells.
Norelli M; Camisa B; Barbiera G; Falcone L; Purevdorj A; Genua M; Sanvito F; Ponzoni M; Doglioni C; Cristofori P; Traversari C; Bordignon C; Ciceri F; Ostuni R; Bonini C; Casucci M; Bondanza A
Nat Med; 2018 Jun; 24(6):739-748. PubMed ID: 29808007
[TBL] [Abstract][Full Text] [Related]
20. Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients.
Hoffmann JM; Schubert ML; Wang L; Hückelhoven A; Sellner L; Stock S; Schmitt A; Kleist C; Gern U; Loskog A; Wuchter P; Hofmann S; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
Front Immunol; 2017; 8():1956. PubMed ID: 29375575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
